<DOC>
	<DOC>NCT00366171</DOC>
	<brief_summary>A one year extension study using flexible doses, 20 or 30 mg daily, of open-label bifeprunox.</brief_summary>
	<brief_title>Open Label Extension Study of Bifeprunox</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>1. Outpatients who have successfully completed Wyeth study 3168A1311US. 2. A signed and dated informed consent form for this study. 3. No major protocol violations in previous study. 1. Clinically important abnormalities noted in preceding shortterm study that have not resolved. 2. Use of prohibited treatments in the preceding shortterm study. 3. Meeting any exclusion criteria for the preceding shortterm study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>66 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Schizophrenia</keyword>
</DOC>